Bookbuild sets price for RVL's Metlifecare selldown at $2.20
The bookbuild satisfies the final condition for Metlifecare's merger with Vision Senior Living and Private Life Care.
Hot Topic
EARNINGS
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
BUSINESSDESK: Retirement village operator Metlifecare has completed the bookbuild for the selldown of shares by its biggest shareholder, Retirement Villages NZ, at a 2.2% discount to their last trading price.
The bookbuild was set at $2.20 apiece compared to Metlifecare's closing price yesterday of $2.25. The sale of the 22.5 million shares reduces RVNZ’s holding in the company to 43.2%.
The bookbuild satisfies the final condition for Metlifecare's merger with Vision Senior Living and Private Life Care, and has already been approved under the Overseas Investment Act and by shareholders.
“The support for the offer has been very strong and whilst we have not been able to satisfy all investor demand received, we have achieved a number of RVNZ’s objectives, including broadening the Metlifecare share register," chairman Peter Brown said.
"We believe the continued support of our new and existing shareholders should also assist in obtaining better value recognition for Metlifecare through our share price over time.”
Metlifecare will get eight new villages in the merger with Vision and Private Life Care Holdings, which are to receive shares in the enlarged company as payment. That boosts its portfolio to 24 villages, three of which are in development.
The number of units will increase to 3902 from 2460, while brownfield and greenfield capacity climbs to 1011 units from 380 units.
The shares will be settled on July 23.
Hannah Lynch
Wed, 18 Jul 2012
Wed, 18 Jul 2012
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Free News Alerts
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Bookbuild sets price for RVL's Metlifecare selldown at $2.20
22242